Owen Hughes - 16 Nov 2023 Form 4 Insider Report for C4 Therapeutics, Inc. (CCCC)

Role
Director
Signature
/s/ Jolie M. Siegel, Attorney-in-Fact
Issuer symbol
CCCC
Transactions as of
16 Nov 2023
Net transactions value
$0
Form type
4
Filing time
20 Nov 2023, 16:21:34 UTC
Previous filing
04 Oct 2023
Next filing
10 Jan 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CCCC Stock Option (Right to Buy) Award $0 +52,000 $0.000000 52,000 16 Nov 2023 Common Stock 52,000 $1.82 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 33% of the shares underlying this option shall vest and become exercisable on November 16, 2024, with the remainder vesting in eight equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.